233 related articles for article (PubMed ID: 37279268)
1. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
[TBL] [Abstract][Full Text] [Related]
2. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.
Chan KL; Gomez J; Cardinez C; Kumari N; Sparbier CE; Lam EYN; Yeung MM; Garciaz S; Kuzich JA; Ong DM; Brown FC; Chan YC; Vassiliadis D; Wainwright EN; Motazedian A; Gillespie A; Fennell KA; Lai J; House IG; Macpherson L; Ang CS; Dawson SJ; Beavis PA; Wei AH; Burr ML; Dawson MA
Cancer Cell; 2022 Oct; 40(10):1190-1206.e9. PubMed ID: 36179686
[TBL] [Abstract][Full Text] [Related]
4. Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression.
Bhat KP; Truax AD; Brooks JK; Greer SF
Immunol Cell Biol; 2010; 88(8):807-16. PubMed ID: 20351748
[TBL] [Abstract][Full Text] [Related]
5. NLRC5: a newly discovered MHC class I transactivator (CITA).
Meissner TB; Li A; Kobayashi KS
Microbes Infect; 2012 Jun; 14(6):477-84. PubMed ID: 22209772
[TBL] [Abstract][Full Text] [Related]
6. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
[TBL] [Abstract][Full Text] [Related]
7. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins.
Robbins GR; Truax AD; Davis BK; Zhang L; Brickey WJ; Ting JP
J Biol Chem; 2012 Jul; 287(29):24294-303. PubMed ID: 22645137
[TBL] [Abstract][Full Text] [Related]
8. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
9. The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.
León Machado JA; Steimle V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499042
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.
Bhat KP; Truax AD; Greer SF
J Biol Chem; 2010 Aug; 285(34):25893-903. PubMed ID: 20538595
[TBL] [Abstract][Full Text] [Related]
11. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
[TBL] [Abstract][Full Text] [Related]
12. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA.
Schnappauf F; Hake SB; Camacho Carvajal MM; Bontron S; Lisowska-Grospierre B; Steimle V
Eur J Immunol; 2003 Aug; 33(8):2337-47. PubMed ID: 12884309
[TBL] [Abstract][Full Text] [Related]
13. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
14. Expression of MHC II genes.
Drozina G; Kohoutek J; Jabrane-Ferrat N; Peterlin BM
Curr Top Microbiol Immunol; 2005; 290():147-70. PubMed ID: 16480042
[TBL] [Abstract][Full Text] [Related]
15. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
[TBL] [Abstract][Full Text] [Related]
16. CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression.
Downs I; Vijayan S; Sidiq T; Kobayashi KS
Biofactors; 2016 Jul; 42(4):349-57. PubMed ID: 27087581
[TBL] [Abstract][Full Text] [Related]
17. Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.
Beaulieu YB; Leon Machado JA; Ethier S; Gaudreau L; Steimle V
PLoS One; 2016; 11(2):e0148753. PubMed ID: 26871568
[TBL] [Abstract][Full Text] [Related]
18. Adenosine signaling inhibits CIITA-mediated MHC class II transactivation in lung fibroblast cells.
Fang M; Xia J; Wu X; Kong H; Wang H; Xie W; Xu Y
Eur J Immunol; 2013 Aug; 43(8):2162-73. PubMed ID: 23681904
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of CIITA transcriptional function by ubiquitin.
Greer SF; Zika E; Conti B; Zhu XS; Ting JP
Nat Immunol; 2003 Nov; 4(11):1074-82. PubMed ID: 14528304
[TBL] [Abstract][Full Text] [Related]
20. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
Ludigs K; Seguín-Estévez Q; Lemeille S; Ferrero I; Rota G; Chelbi S; Mattmann C; MacDonald HR; Reith W; Guarda G
PLoS Genet; 2015 Mar; 11(3):e1005088. PubMed ID: 25811463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]